Related Experiment Video

Updated: May 11, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer

Andrea Bisso1, Michela Faleschini, Federico Zampa

  • 1Laboratorio Nazionale CIB, AREA Science Park, Trieste, Italy.

Cell Cycle (Georgetown, Tex.)
|May 10, 2013
PubMed

Insights

MicroRNAs miR-181a/b negatively regulate DNA damage response in aggressive breast cancers by impacting ATM kinase. Their expression predicts triple-negative breast cancer sensitivity to PARP1 inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer is a complex disease with diverse molecular features influencing patient outcomes.
  • MicroRNAs (miRNAs) are key regulators of gene expression, acting as oncogenes or tumor suppressors.
  • Aberrant miRNA expression is implicated in various cancers, including breast cancer.

Purpose of the Study:

  • To investigate the role of miR-181a/b in breast cancer.
  • To determine the impact of miR-181a/b on the DNA damage response pathway.
  • To explore the potential of miR-181a/b as predictive biomarkers for targeted therapies.

Main Methods:

  • Analysis of miR-181a/b expression in breast cancer tissues.
  • Assessment of the correlation between miR-181a/b levels and tumor aggressiveness.
  • Investigation of the effect of miR-181a/b on ataxia telangiectasia mutated (ATM) kinase activity.
  • Evaluation of miR-181a/b deregulation in triple-negative breast cancer cells treated with poly-ADP-ribose-polymerase1 (PARP1) inhibitors.

Main Results:

  • miR-181a and miR-181b were overexpressed in more aggressive breast cancers.
  • Expression of miR-181a/b inversely correlated with ATM levels.
  • Deregulated miR-181a/b expression influenced the sensitivity of triple-negative breast cancer cells to PARP1 inhibition.

Conclusions:

  • miR-181a/b function as negative regulators of the DNA damage response in breast cancer by targeting ATM.
  • Monitoring miR-181a/b expression may aid in selecting patients for PARP1 inhibitor therapy.
  • These findings suggest potential therapeutic strategies for breast and other cancers based on miR-181a/b levels.
Keywords:
ATMBRCA1BRCAnessDNA damage responsePARP inhibitorsbreast cancermicroRNA

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...